Analysis of pharmacogenomic very important pharmacogenomic variants: CYP3A5, ACE, PTGS2 and NAT2 genes in Chinese Bai population.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY Personalized medicine Pub Date : 2022-09-01 Epub Date: 2022-07-08 DOI:10.2217/pme-2021-0157

Wenting Meng, Wenjie Zhang, Shuangyu Yang, Xia Dou, Yuanwei Liu, Haiyue Li, Jianfeng Liu, Tianbo Jin, Bin Li

{"title":"Analysis of pharmacogenomic very important pharmacogenomic variants: CYP3A5, ACE, PTGS2 and NAT2 genes in Chinese Bai population.","authors":"Wenting Meng, Wenjie Zhang, Shuangyu Yang, Xia Dou, Yuanwei Liu, Haiyue Li, Jianfeng Liu, Tianbo Jin, Bin Li","doi":"10.2217/pme-2021-0157","DOIUrl":null,"url":null,"abstract":"Aim: Our study aimed to screen the genotype frequencies of very important pharmacogenomic (VIP) mutations and identify their differences between Bai and other populations. Materials & methods: We selected 66 VIP variants from PharmGKB (www.pharmgkb.org/) for genotyping. χ2 test was used to identify differences in loci between these populations and FST values of Bai and the other 26 populations were analyzed. Results: Our study showed that the frequencies of SNPs of CYP3A5, ACE, PTGS2 and NAT2 differed significantly from those of the other 26 populations. At the same time, we found that some VIP variants may affect the metabolism of drugs and the genetic relationship between the Bai population and East Asian populations was found to be the closest. Conclusion: By comparing the genotype frequencies of different populations, the loci with significant differences were identified and discussed, providing a theoretical basis for individualized drug use in the Bai ethnic population.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0157","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Our study aimed to screen the genotype frequencies of very important pharmacogenomic (VIP) mutations and identify their differences between Bai and other populations. Materials & methods: We selected 66 VIP variants from PharmGKB (www.pharmgkb.org/) for genotyping. χ2 test was used to identify differences in loci between these populations and FST values of Bai and the other 26 populations were analyzed. Results: Our study showed that the frequencies of SNPs of CYP3A5, ACE, PTGS2 and NAT2 differed significantly from those of the other 26 populations. At the same time, we found that some VIP variants may affect the metabolism of drugs and the genetic relationship between the Bai population and East Asian populations was found to be the closest. Conclusion: By comparing the genotype frequencies of different populations, the loci with significant differences were identified and discussed, providing a theoretical basis for individualized drug use in the Bai ethnic population.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国白族人群CYP3A5、ACE、PTGS2和NAT2基因的药物基因组学分析。

目的:筛选白族重要药物基因组(VIP)突变的基因型频率，确定其与其他人群的差异。材料与方法:从PharmGKB (www.pharmgkb.org/)中选择66个VIP变异进行基因分型。采用χ2检验检验这些种群的基因座与白族的FST值的差异，并对其余26个种群的FST值进行分析。结果:我们的研究表明，CYP3A5、ACE、PTGS2和NAT2的snp频率与其他26个人群有显著差异。同时，我们发现一些VIP变异可能影响药物的代谢，并且发现白族人群与东亚人群的遗传关系最密切。结论:通过比较不同人群的基因型频率，发现并探讨了具有显著差异的基因座，为白族人群个体化用药提供了理论依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.